[en] It is now well accepted that a chronic, low-grade inflammation is observed in abdominal obesity, insulin resistance and type 2 diabetes mellitus, and that pro-inflammatory cytokines and oxidative stress play a role in the pathogenesis of type 2 diabetes. These new findings raise the question of whether antiinflammatory strategies may have a place in the prevention and treatment of type 2 diabetes. This review article describes the results obtained in studies on patients with metabolic syndrome or type 2 diabetes aiming to test the metabolic effect of anti-inflammatory (salicylates, antagonists of interleukine-1, antagonists of tumor necrosis factor-alpha) and anti-oxydants (succinobucol) drugs.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-801. (Pubitemid 44033299)
Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34. (Pubitemid 32656163)
Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study. Diabetes 2003;52:812-7. (Pubitemid 36323590)
*Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7. (Pubitemid 46024993)
Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30. (Pubitemid 38063705)
Olefsky JM, Glass CK. Macrophages, inflammation and insulin resistance. Annu Rev Physiol 2010;72:219-46.
Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger ? Science 2010;327:296-300.
*Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
*Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother 2010;44:1207-21.
Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science 2001;293:1673-7. (Pubitemid 32807849)
Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb Exp Pharmacol 2011;203:257-78.
Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: Risk reduction in a chronic inflammatory disease. Arthritis Care Res 2011;63:512-21.
Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. BMJ 1901;1:760-2.
Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. BMJ 1957;2:1071-4.
Hecht A, Goldner MG. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism 1959;8:418-28.
Gilgore SG. The influence of salicylate on hyperglycemia. Diabetes 1960;9:392-3.
McCarty MF. Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. Med Hypotheses 2010;75:276-81.
Kopp E, Ghosh S. Inhibition of NF-kB by sodium salicylate and aspirin. Science 1994; 265:956-9.
Pierce JW, Read MA, Ding H, et al. Salicylates inhibit I k B-α phosphorylation, endothelial-leukocyt adhesion molecule expression, and neutrophil transmigration. J Immunol 1996;156:3961-9. (Pubitemid 26137683)
Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity ok I(k)B kinase-β. Nature 1998;396:77-80. (Pubitemid 28520452)
Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-6. (Pubitemid 34546896)
Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008;1:36-43.
Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-94. (Pubitemid 351213338)
Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: Results of a randomised doubleblind placebo-controlled study. Diabetologia 2009;52:385-93.
*Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial. Ann Intern Med 2010;152:346-57.
Chai W, Liu J, Jahn LA, et al. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care 2011;34:1634-8.
Ehses JA, Böni-Schnetzler M, Faulenbach M, Donath MY. Macrophages, cytokines and beta-cell death in type 2 diabetes. Biochem Soc Trans 2008;36:340-2. (Pubitemid 351839327)
Carstensen M, Herder C, Kivimäki M, et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010;59:1222-7.
Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32.
*Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26. (Pubitemid 46588416)
Luotola K, Pietilä A, Zeller T, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med 2011;269:322-32.
Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-8.
Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
Araujo EP, De Souza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 2007;148:5991-7. (Pubitemid 350146162)
Paquot N, Castillo MJ, Lefèbvre PJ, Scheen AJ. No increased insulin sensitivity after a single intraveinus administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000;85:1316-9. (Pubitemid 32269392)
Bernstein LE, Berry J, Kim S, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006;166:902-8.
Ofei F, Hurel S, Newkirk J, et al. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5. (Pubitemid 26225502)
Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-α blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517-25. (Pubitemid 41527607)
Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004;34:641-2. (Pubitemid 39331479)
Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosis spondylitis. Ann Rheum Dis 2005;64:765-6. (Pubitemid 40559306)
Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.
Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8. (Pubitemid 47201685)
Oguz FM, Oguz A, Unzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg 2007;62:218-22. (Pubitemid 47234750)
Seriolo B, Ferrone C, Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: Relationship between insulin resistance and disease activity. J Rheumatol 2008;35:355-7. (Pubitemid 351281162)
Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxydative stress and stress-activated signalling pathways: An unifying hypothesis of type 2 diabetes. Endocrin Rev 2002;23:599-622. (Pubitemid 35191625)
Muldrew KM, Franks AM. Succinobucol: Review of the metabolic, antiplatelet and cardiovascular effects. Expert Opin Investig Drugs 2009;18:531-9.
*Tardif JC, McMurray JJ, Klug E, et al. Aggressive reduction of inflammation stops events (ARISE) trial investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: A randomised, double-blind, placebo-controlled trial. Lancet 2008;371:1761-8. (Pubitemid 351697951)
Gorogawa S, Kajimoto Y, Umayahara Y, et al. Probucol preserves pancreatic beta-cell function through reduction oxydative stress in type 2 diabetes. Diabetes Res Clin Pract 2002;57:1-10. (Pubitemid 34463014)
Stocker R. Molecular mechanism underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues. Curr Opin Lipidol 2009;20:227-35.
Sathyapalan T, Atkin SL. Is there a role for immune and anti-inflammatory therapy in type 2 diabetes ? Minerva Endocrinol 2011;36:147-56.
*Goldfine AB, Fonseca V, Shoelson SE. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem 2011;57:162-7.
Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 2011;32:543-50.
Hara T, Hirasawa A, Ichimura A, Kimura I, Tsujimoto G. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J Pharm Sci 2011;100:3594-601.
Mitroulis I, Skendros P, Ritis K. Targeting IL-1b in disease: The expanding role of NLRP3 inflammasome. Eur J Intern Med 2010;21:157-61.
Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179-88.
